Evidence map›Paper›PMID 39759366›Full record

ArticleHeliyon2024

Plasma-based transcriptomic non-coding signature for predicting relapse in pediatric acute lymphoblastic leukemia.

Yaping Wang, Xiaopeng Ma, Huimin Li, Ji'ou Zhao, Meiyun Kang, Liucheng Rong, Yao Xue, Jiali Wang, Junwei Tang, Yongjun Fang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yaping WangDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Xiaopeng MaDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Huimin LiDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Ji'ou ZhaoDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Meiyun KangDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Liucheng RongDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Yao XueDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Jiali WangDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.
Junwei TangDepartment of General Surgery, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China.
Yongjun FangDepartment of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 72# Guangzhou Road, Nanjing, Jiangsu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric Acute Lymphoblastic Leukemia (ALL) is the most common malignant tumor of the hematological system in children, and its relapse after treatment has consistently been a significant factor hindering prognosis. This study aimed to develop a blood-based non-invasive method for predicting relapse in children with ALL. Two cohorts of pediatric ALL patients were analyzed. Through high-throughput profiling, three miRNAs and three circRNAs were identified as potential biological markers, exhibiting a gradient increase in expression from healthy controls to the relapsed group. Logistic regression analysis revealed the superior predictive ability of the combined non-coding RNA panel compared to individual groups. A nomogram incorporating the non-coding RNA panel and other clinical risk features was developed. Combining the non-coding RNA panel with relevant risk features could enhance predictive accuracy. The non-coding RNA panel remained an independent predictor of relapse in the validation cohort, and its combination with clinical features formed a superior risk stratification model. In conclusion, this blood-based non-invasive method holds promise for predicting relapse in pediatric ALL patients at the time of initial diagnosis. The non-coding RNA panel, along with clinical risk features, may significantly impact patient care and outcomes.

Indexed as

FingerprintLeukemiaMRDRecurrenceRisk score

Identifiers

PMID39759366
PMCPMC11700237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.